By admin 
The Rudensky Symposium on Immunity, Inflammation and Tolerance, held on August 27–28, 2026, transcended the conventional boundaries of a scientific conference, serving as both a pivotal academic gathering and a heartfelt tribute. Convening at Memorial Sloan Kettering Cancer Center (MSKCC), the event marked the 70th birthday of Dr. Alexander "Sasha" Rudensky, PhD, a towering figure in immunology whose pioneering work has fundamentally reshaped our understanding of immune regulation. The symposium brought together an illustrious assembly of former trainees, long-standing collaborators, and esteemed colleagues, reflecting a professional network built over decades of shared scientific endeavor and personal camaraderie. Scientific presentations, showcasing the latest breakthroughs across diverse immunological fields, were seamlessly interwoven with poignant shared memories, collectively illuminating the profound impact of Dr. Rudensky’s mentorship and the enduring friendships that have shaped countless lives and careers within the scientific community.
The Cancer Research Institute (CRI), a leading non-profit organization dedicated to advancing immunotherapy, proudly supported this landmark symposium, recognizing Dr. Rudensky as a distinguished member of its Scientific Advisory Council (SAC). For over two decades, CRI has been a steadfast advocate and financial backer of Dr. Rudensky’s groundbreaking research and his exceptional commitment to nurturing the next generation of scientists. This enduring partnership has facilitated the training of more than a dozen CRI-funded fellows within his laboratory, many of whom have gone on to establish their own impactful research programs. In 2015, Dr. Rudensky’s transformative contributions were formally recognized with the prestigious CRI William B. Coley Award for his seminal discoveries concerning regulatory T cells, or Tregs. These specialized immune cells are now understood to be critical orchestrators of immune homeostasis, reining in excessive immune responses and safeguarding healthy tissues from inflammatory damage, a mechanism vital for preventing autoimmune diseases and shaping responses to cancer. CRI’s deep connections within this scientific community underscore its unwavering commitment to funding both fundamental immunology and its direct applications in cancer immunology, operating on the principle that a profound understanding of the immune system’s basic functions is indispensable for effectively harnessing its power against malignancy.
A Pioneer’s Journey: Dr. Alexander Rudensky’s Enduring Legacy
Dr. Alexander Rudensky’s journey to becoming a preeminent immunologist began with a foundational curiosity about the intricate mechanisms governing immune responses. Born in 1956, his career trajectory has been marked by relentless intellectual pursuit and a series of paradigm-shifting discoveries. After receiving his Ph.D. from the Gabrichevsky Research Institute of Epidemiology and Microbiology in Moscow, Russia, his scientific odyssey led him to the United States, where he embarked on postdoctoral research that would eventually lay the groundwork for his most celebrated contributions.
His most profound impact stems from his pioneering work on regulatory T cells (Tregs). While the existence of cells capable of suppressing immune responses had been hypothesized, Dr. Rudensky’s laboratory was instrumental in definitively identifying the key molecular markers and transcriptional programs that define Tregs, particularly the Foxp3 transcription factor. His research elucidated how these cells develop, differentiate, and exert their immunosuppressive functions. This discovery was not merely academic; it fundamentally altered our understanding of how the immune system maintains self-tolerance, preventing autoimmune diseases like type 1 diabetes, multiple sclerosis, and rheumatoid arthritis. Prior to his work, the precise mechanisms underlying immune tolerance were largely enigmatic. Dr. Rudensky’s findings provided a molecular and cellular blueprint, opening vast new avenues for therapeutic intervention in autoimmune disorders and, crucially, in cancer immunotherapy, where modulating Treg activity can either enhance or suppress anti-tumor immunity.
Joining MSKCC, where he now heads the Immunology Program and is an Investigator with the Howard Hughes Medical Institute (HHMI), Dr. Rudensky fostered an environment of rigorous scientific inquiry and collaborative mentorship. His lab became a crucible for training a new generation of immunologists, many of whom have gone on to lead their own highly successful research groups, a testament to his profound influence as an educator and mentor. The 2015 CRI William B. Coley Award, a recognition bestowed upon scientists for outstanding discoveries in basic and tumor immunology, underscored the clinical relevance of his basic science. The award committee highlighted his "pioneering work on the identification and characterization of regulatory T cells," emphasizing how this foundational research has provided critical insights into how the immune system distinguishes between self and non-self, a distinction often blurred in the context of cancer.
CRI’s Investment in Foundational Discovery and Future Leaders
The Cancer Research Institute’s long-standing partnership with Dr. Rudensky exemplifies its broader strategic vision: that groundbreaking advances in cancer treatment are inextricably linked to a deep understanding of fundamental immunology. Since its inception over 70 years ago, CRI has been at the forefront of supporting basic scientific inquiry, often years before its clinical implications become apparent. This forward-thinking approach has been instrumental in numerous immunotherapy breakthroughs.
CRI’s investment in Dr. Rudensky’s lab extends beyond direct research funding. The organization’s commitment to fostering scientific talent is evident in its robust fellowship programs. Over a dozen CRI-funded postdoctoral fellows have passed through Dr. Rudensky’s laboratory, benefiting from his unparalleled expertise and mentorship. These fellowships provide critical early-career support, enabling promising young scientists to pursue innovative research projects under the guidance of world-renowned investigators. This pipeline of talent ensures that Dr. Rudensky’s scientific legacy, characterized by intellectual rigor and a pursuit of fundamental truths, continues to propagate through the next generation of immunologists. Dr. Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at CRI, reiterated this commitment, stating, "Supporting scientists like Dr. Rudensky and his trainees is at the very core of CRI’s mission. Their foundational discoveries don’t just expand our knowledge; they lay the groundwork for the next generation of cancer therapies that will save countless lives."
Unveiling the Interconnectedness of Health and Disease: Symposium Highlights
The scientific discussions at the Rudensky Symposium painted a comprehensive picture of immunology’s expanding frontiers, demonstrating how processes that maintain healthy tissues also critically influence cancer development, progression, and response to treatment. The overarching theme that emerged was the intricate interplay between immune cells, the tissue microenvironment, and systemic factors, highlighting how basic biological questions often yield profound insights relevant to cancer prevention and therapy.
Basic Science Reveals How Tissues Stay in Balance
Several presentations underscored the importance of fundamental immunology, revealing principles with far-reaching implications for cancer research. Dr. Ruslan Medzhitov, a distinguished CRI scientist and 2003 CRI Coley Awardee from Yale University, described novel functions of macrophages. His research illustrated how stressed cells recruit macrophages not just as defenders against infection, but as sophisticated "tissue maintenance crews" tasked with removing damaged proteins and cellular debris. This concept expands the role of immune cells beyond immunity, suggesting a crucial involvement in tissue repair and homeostasis, a process that can go awry in chronic inflammation and cancer.
The symposium also highlighted the multifaceted roles of Tregs, extending beyond their well-known function of suppressing immune responses. Dr. Diane Mathis, a 2024 CRI Coley Awardee from Harvard Medical School, presented compelling evidence on distinct Treg populations that actively participate in tissue repair. Her work in injured muscle models demonstrated how these Tregs control inflammation, guide regenerative processes, and limit scarring, suggesting potential therapeutic avenues for chronic inflammatory conditions and tissue damage. Complementing this, Dr. Christophe Benoist, also a 2024 CRI Coley Awardee from Harvard Medical School, revealed that the specific molecular target recognized by a Treg plays a crucial role in determining its identity and function. These findings offer granular insights into Treg heterogeneity, paving the way for more precise immunomodulatory strategies that can selectively tune immune responses without broadly compromising immune surveillance. The precision required for immune regulation was a recurring motif, with experts emphasizing that too little restraint can lead to debilitating autoimmunity and tissue destruction, while excessive suppression can unfortunately create an environment conducive to cancer immune escape.
Can Immunity Act Before Cancer Takes Hold? Early Immunosurveillance
A significant portion of the symposium focused on the intriguing possibility of immune intervention even before a visible tumor forms, a concept known as early cancer immunosurveillance. Dr. Richard A. Flavell, a CRI scientist and 2012 CRI Coley Awardee from Yale University, presented groundbreaking work exploring how the immune system might detect and eliminate mutant cells at their nascent stages. Studying mutant intestinal stem cells in mouse models, his team observed that while cells carrying a cancer-linked BRAF mutation gained a competitive survival advantage, a significant proportion were still eliminated. These experiments strongly suggested that immune recognition is a critical determinant of which abnormal cells survive early in the process. When these mutant cells lost a molecule essential for communicating with T cells, they were more likely to proliferate unchecked within the small intestinal stem cell compartments. Furthermore, Tregs and the immune signal IL-10 appeared to play a role in restraining these early clones, offering tantalizing hints about natural immune mechanisms that might prevent cancer initiation. While preclinical, this work presents a powerful concept: the immune system may influence cancer development from the moment a potentially dangerous cell emerges and begins to compete with its normal neighbors, opening new frontiers for cancer prevention.
Approaching the inflammation-cancer connection from another angle, Dr. Julien C. Marie, from the Université Lyon 1, discussed how disrupting a key regulatory signal, TGF-β, in mice could push intestinal Th17 cells—another type of immune cell—into a state of persistent inflammation. This chronic inflammatory environment was directly associated with localized DNA damage and, eventually, cancer development. Critically, restoring the TGF-β signal reversed aspects of this harmful state, suggesting that even established inflammatory programs linked to carcinogenesis may retain a degree of flexibility and could potentially be modulated therapeutically.
Cancer Depends on Its Wider Ecosystem: The Tumor Microenvironment
The symposium also highlighted the intricate relationship between cancer and its surrounding ecosystem, including the gut microbiome and the physical scaffolding of tissues. Dr. Dan Littman, a CRI SAC member and 2016 CRI Coley Awardee from New York University, elucidated the profound connection between the gut microbiome and responses to cancer immunotherapy. His preclinical research demonstrated how specific gut bacteria can "train" T cells, influencing their activation and efficacy, thereby modulating responses to checkpoint immunotherapy. This work illustrates how immune responses initiated in the intestine can have systemic effects, impacting cancer progression and treatment outcomes in distant parts of the body, offering a promising avenue for enhancing existing therapies through microbiome modulation.
Dr. Paula D. Bos, from Virginia Commonwealth University, presented innovative research on how Tregs can influence breast cancer progression through their interactions with macrophages and the extracellular matrix surrounding a tumor. Her studies showed that temporarily depleting Tregs in mouse tumors shifted macrophages toward a tumor-fighting (anti-tumorigenic) state and disrupted the highly aligned collagen fibers that can act as "highways" for cancer cell escape. This intervention resulted in fewer circulating tumor cells and reduced metastatic disease in the mice. Dr. Bos emphasized that the goal is not a broad elimination of Tregs, which could lead to harmful autoimmune responses, but rather to reveal more specific ways to influence macrophage behavior and halt tumor spread, highlighting the need for highly targeted approaches.
Further exploring how tumors create immune-suppressive "neighborhoods," Dr. Nicholas Arpaia, from Columbia University, identified a specific fibroblast population that actively recruits suppressive Tregs around lung tumors. Understanding these cellular interactions is crucial for dismantling the tumor’s protective shield. Dr. Arpaia also described collaborative work with CRI Lloyd J. Old STAR and CRI-funded scientist Dr. Tal Danino, utilizing engineered bacteria to deliver therapies directly into tumors. This innovative strategy aims to concentrate immune-modulating treatments precisely where they are needed, minimizing systemic side effects and maximizing therapeutic impact, representing a significant step toward precision oncology.
Progress Begins with People: The Enduring Power of Mentorship and Collaboration
Beyond the groundbreaking scientific data, the Rudensky Symposium served as a powerful reminder that advances in cancer research are not merely the product of isolated experiments but grow organically from fundamental questions about immune cells, tissues, and their complex interactions. Crucially, it underscored that such progress is inextricably linked to robust mentorship, collaborative spirit, rigorous scientific discourse, and the intellectual freedom to pursue questions whose clinical relevance may not be immediately obvious.
The gathering of generations of scientists—from seasoned professors to aspiring postdoctoral fellows—all connected by their association with Dr. Rudensky, made the ripple effect of mentorship profoundly tangible. Speakers and attendees alike shared anecdotes illustrating Dr. Rudensky’s unparalleled dedication to nurturing scientific curiosity, fostering critical thinking, and empowering his trainees to forge their own intellectual paths. This vibrant exchange of ideas and personal reflections exemplified how trainees evolve into mentors, how initial discoveries inform entirely new scientific fields, and how sustained collaborations bridge fundamental biological questions with the ultimate shared goal of improving patients’ lives.
For more than 70 years, the Cancer Research Institute has strategically invested in this foundational ecosystem of discovery, recognizing that supporting both the science and the exceptional individuals who carry it forward is paramount. The Rudensky Symposium brought this long-term commitment to vivid life, illustrating the dynamic interplay between scientific exploration, professional development, and human connection. As the scientific community looks to the future, the principles celebrated at this symposium—curiosity-driven research, dedicated mentorship, and collaborative innovation—will undoubtedly continue to drive the next wave of breakthroughs in immunology and cancer therapy, moving closer to a world where cancer is a treatable, and perhaps even preventable, disease.
